Business Context and Reporting Period
Company: BiomX Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2026
Event: Entry into a Material Definitive Agreement (Share Purchase and Option Agreement) with Mayers Ventures LLC.
Key Financial Metrics and Transaction Details
This filing reports a strategic acquisition rather than periodic financial performance. No revenue, profit, cash flow, or debt metrics for BiomX Inc. are provided in this document.
- Acquisition Target: 10% equity interest (324,573 shares) in M.E.A. Testing Systems Ltd. (MEA) and its affiliated Indian company.
- Consideration Paid: $50,000 cash plus 1,300,000 restricted BiomX common shares.
- Strategic Asset: Exclusive, perpetual worldwide license to MEA's technology, specifically drone testing solutions and electric motor validation systems.
- Future Option: BiomX holds an exclusive option until June 30, 2028, to acquire the remaining ~78.9% of MEA.
- Option Valuation Basis: If exercised, the price will be the greater of (i) 2x MEA's net revenue or (ii) 4x MEA's EBITDA for the fiscal year ending December 31, 2027.
Material Changes and Conditions
The transaction represents a material change in BiomX's asset base and strategic direction, focusing on defense systems and electric propulsion. The closing of the initial purchase is subject to:
- Approval by NYSE American of a supplemental listing application for the new shares.
- Execution of a license agreement granting BiomX exclusive rights to MEA's technology.
- Completion of due diligence for the future option exercise.
Guidance, Risks, and Contingencies
Management Commentary: The acquisition is intended to strengthen BiomX's support for integrated defense systems by adding expertise in electric propulsion for unmanned aerial platforms.
Risks and Contingencies:
- Regulatory Approval: Issuance of consideration shares is contingent on NYSE American approval.
- Due Diligence: The exercise of the option to acquire the remaining stake is subject to BiomX's sole discretion based on due diligence results.
- Forward-Looking Statements: Actual results may differ materially from expectations regarding transaction benefits and completion.
- Exclusivity: Mayers Ventures has agreed not to solicit other offers for MEA until the option exercise date.
Investor Verification Checklist
- Verify the status of the NYSE American supplemental listing application for the 1.3 million new shares.
- Confirm the execution of the exclusive technology license agreement with MEA.
- Review the audited financial statements of MEA for the fiscal year ending December 31, 2027, to assess the potential cost of the future option exercise.
- Monitor BiomX's capital structure for dilution resulting from the issuance of restricted shares.
- Assess the strategic fit of MEA's drone testing technology with BiomX's existing defense portfolio.